Media: The US Considers Strict Restrictions on Medicines from China
According to a draft executive order quoted by The New York Times, the Trump administration is considering strict restrictions on medicines imported from China.
The article material states: "This executive order may block experimental drugs developed in China from entering."
It is reported that this draft executive order has been distributed to investors and large pharmaceutical companies. The draft mentions that China "and other hostile actors" have exploited the loopholes in the United States' "scientifically open regulatory system." The document also calls for increasing the production capacity of several key drugs produced in China in the United States.
The newspaper points out that large pharmaceutical companies are acquiring patent rights for drugs developed in China for the treatment of cancer, obesity, cardiovascular diseases, and Crohn's disease. According to the newspaper's assessment, this could fundamentally change the U.S. pharmaceutical industry and affect the accessibility of generic drugs and advanced drug therapies.
Kush Dasai, White House Deputy Press Secretary, told the media that the government was not "actively considering" the draft executive order.
Original: www.toutiao.com/article/1842875465817225/
Statement: This article represents the views of the author(s) alone